Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01216254
Recruitment Status : Unknown
Verified January 2012 by Jacek Zielinski, Medical University of Gdansk.
Recruitment status was:  Recruiting
First Posted : October 7, 2010
Last Update Posted : January 31, 2012
Sponsor:
Information provided by (Responsible Party):
Jacek Zielinski, Medical University of Gdansk

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to assess the outcomes of breast conserving therapy operation depending on the type of surgical tool used: classic electrocoagulation with higher operative temperatures and high frequency electrocoagulation with lower operative temperatures. The investigators would assess the pain levels, length and amount of the lymphatic secretion as well as quality of life following breast conserving surgery.

Condition or disease Intervention/treatment Phase
Breast Cancer Device: classic v high-frequency electrocoagulation Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation.
Study Start Date : October 2010
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Classic electrocoagulation
Arm of the study where the classic low-frequency electrocoagulation is used during the operation
 Device: classic v high-frequency electrocoagulation
During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
Other Name: Ellmann
Experimental: High Frequency electrocoagulation
Arm of the study where the tested high-frequency electrocoagulation is used during the operation
 Device: classic v high-frequency electrocoagulation
During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
Other Name: Ellmann


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pain Control [ Time Frame: From the day before surgery up to 12 weeks (+/-2days) after surgery ]
    Pain assessment would be performed using Visual Analogue Scale (VAS) at the days 1-5, 10 (+/- 2), 20 (+/- 2), 30 (+/- 2), and 12 weeks (+/- 2 days). SF - MPQ questionnaire would be filled in on admission, 10th (+/- 2) post-operative day and 12 weeks (+/- 2 days)after surgery.


Secondary Outcome Measures :
  1. Quality of life (QoL) [ Time Frame: From the day before surgery up to 12 weeks (+/-2days) after surgery ]
    Pre-operative assessment of QoL would be performed by psychologist using questionnaires: CISS, HADS - M, Eysencka. Postoperative assessment of QoL would be performed using QLQ C30 and QLQ BR 23 questionnaires 12 weeks (+/- 2 days)after surgery

  2. Length of lymphatic secretion [ Time Frame: From the day before surgery up to 12 weeks (+/-2days) after surgery ]
    Number of days of lymphatic secretion would be assessed.

  3. Amount of lymphatic secretion [ Time Frame: From the day before surgery up to 12 weeks (+/-2days) after surgery ]
    Amount of lymphatic secretion would be measured until it stops on daily basis.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • female
  • age 18-100
  • breast cancer
  • stage IIA and II B (cT1a-3; cN0-1; cM0)
  • no previous breast surgery
  • no previous cancer
  • obtained informed consent

Exclusion Criteria:

  • stages I, III, IV
  • localised breast infection
  • previous breast surgery for any cause
  • previous cancer
  • no voluntary consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01216254


Contacts
Layout table for location contacts
Contact: Jacek Zielinski, M.D., Ph.D. +48583492440 jaziel@gumed.edu.pl
Contact: Maciej Bobowicz, M.D. +48608738614 mbobowicz@gumed.edu.pl

Locations
Layout table for location information
Poland
Department of Surgical Oncology Recruiting
Gdansk, Pomorskie, Poland, 80-211
Principal Investigator: Jacek Zielinski, M.D., Ph.D.         
Sub-Investigator: Maciej Bobowicz, M.D.         
Sub-Investigator: Iwona Chruscicka, M.D., Ph.D.         
Sub-Investigator: Piotr Rak, M.D., Ph.D.         
Sub-Investigator: Pawel Kabata, M.D.         
Sub-Investigator: Radoslaw Jaworski, M.D., Ph.D.         
Sponsors and Collaborators
Medical University of Gdansk
Investigators
Layout table for investigator information
Principal Investigator: Jacek Zielinski, M.D., Ph.D. Medical University of Gdansk
Study Director: Janusz Jaskiewicz, M.D., Ph.D. Medical University of Gdansk
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Jacek Zielinski, Assistant Profesor, Medical University of Gdansk
ClinicalTrials.gov Identifier: NCT01216254    
Other Study ID Numbers: NKEBN/219/2010
First Posted: October 7, 2010    Key Record Dates
Last Update Posted: January 31, 2012
Last Verified: January 2012
Keywords provided by Jacek Zielinski, Medical University of Gdansk:
breast cancer
stage 2
breast conserving therapy
sentinel lymph node dissection
high frequency electrocoagulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases